Thomas Büttner

10PUBLICATIONS
91CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsiesPredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 07, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Jul 22, 2025
Association of fluid management during robotic-assisted radical laparoscopic prostatectomy with early surgical clinical outcomes: a risk factor for lymphoceles.

Thomas Büttner, Marcus O Thudium, Manuel Ritter

|Jul 08, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Mimma Rizzo, Andrey Soares, Shilpa Gupta

|Jan 08, 2025
Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center.

Thomas Büttner, Philipp Lossin, Stefan Latz

|May 16, 2024
Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.

Thomas Büttner, Niklas Klümper, Richard Weiten

Pageof 2

Frequent Collaborators

5 joint publications

Jörg Ellinger

3 joint publications

Niklas Klümper

3 joint publications

Philipp Krausewitz

2 joint publications

Christopher Darr